| Literature DB >> 25582198 |
Qian Zhang1, Qingchao Tang1, Dandan Qin2, Lei Yu1, Rui Huang1, Guixiang Lv3, Zhaoxia Zou3, Xiao-chen Jiang3, Chendan Zou3, Wei Liu3, Jing Luo3, Zhixun Zhao1, Shan Muhammad1, Guiyu Wang1, Ying-gang Chen1, Xishan Wang4.
Abstract
MicroRNAs (miRNAs) are dysregulated in many types of malignant diseases, including colorectal cancer. miRNA 30a (miR-30a) is a member of the miR-30 family and has been implicated in many types of cancers. In this study, we determined the expression of miR-30a in human colon cancer tissues and cell lines. miR-30a was found to be significantly downregulated in both the tissues and cell lines. Furthermore, overexpression of miR-30a inhibited, while silencing of miR-30a promoted, cell proliferation, migration, and invasion in vitro. Consistently, stable overexpression of miR-30a suppressed the growth of colon cancer cell xenografts in vivo. Moreover, bioinformatic algorithms and luciferase reporter assays revealed that insulin receptor substrate 2 (IRS2) is a direct target of miR-30a. Further functional studies suggested that repression of IRS2 by miR-30a partially mediated the tumor suppressor effect of miR-30a. In addition, miR-30a inhibited constitutive phosphorylation of Akt by targeting IRS2. Additionally, clinicopathological analysis indicated that miR-30a has an inverse correlation with the staging in patients with colon cancer. Taken together, our study provides the first evidence that miR-30a suppressed colon cancer cell growth through inhibition of IRS2. Thus, miR-30a might serve as a promising therapeutic strategy for colon cancer treatment.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25582198 PMCID: PMC4333091 DOI: 10.1128/MCB.01242-14
Source DB: PubMed Journal: Mol Cell Biol ISSN: 0270-7306 Impact factor: 4.272